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SUMMARY
This review presents a progression strategy for the discovery of new anti-parasitic drugs that uses in vitro susceptibility,
time-kill and reversibility measures to deﬁne the therapeutically relevant exposure required in target tissues of animal
infection models. The strategy is exempliﬁed by the discovery of SCYX-7158 as a potential oral treatment for stage 2 (CNS)
Human African Trypanosomiasis (HAT). A critique of current treatments for stage 2 HAT is included to provide context
for the challenges of achieving target tissue disposition and the need for establishing pharmacokinetic–pharmacodynamic
(PK–PD) measures early in the discovery paradigm. The strategy comprises 3 stages. Initially, compounds demonstrating
promising in vitro activity and selectivity for the target organism over mammalian cells are advanced to in vitro metabolic
stability, barrier permeability and tissue binding assays to establish that they will likely achieve and maintain therapeutic
concentrations during in-life eﬃcacy studies. Secondly, in vitro time-kill and reversibility kinetics are employed to correlate
exposure (based on unbound concentrations) with in vitro activity, and to identify pharmacodynamic measures that would
best predict eﬃcacy. Lastly, this information is used to design dosing regimens for pivotal pharmacokinetic–
pharmacodyamic studies in animal infection models.
Key words: In vitro susceptibility, time-kill, pharmacokinetics–pharmacodynamics, tissue disposition, benzoxaboroles,
HAT.
INTRODUCTION
Prediction of the therapeutic dose and success of
an anti-parasitic agent requires an understanding
of the complex interaction between the inherent
potency of the agent, the clinically relevant exposure
required within the host’s target tissue and hence
the organism, and the duration that exposure has
to be sustained in that tissue to eﬀect a cure. Potential
disconnects between exposure in plasma and the
target tissue must be considered early to ensure
drug exposure is assessed in the pharmacologically
relevant compartment (Louie et al. 2005). For
example, in malaria, leishmaniasis, human African
trypanosomiasis and African animal trypanosomiasis
the relevant compartments would include blood
erythrocytes, macrophages, brain and testes, respect-
ively.
Determination of an eﬀective dose for a given agent
may be achieved empirically in pre-clinical studies by
establishing a dose–response relationship; however,
this approach is time consuming and requires
extensive use of animal models, often comprising a
large number of animals to overcome the variability
inherent in these studies. Moreover, this approach
may yield complete treatment failures because the
candidate drug lacks the pharmacokinetic properties
to achieve therapeutically relevant exposure even at
the highest doses administered. Thus, for capacity,
timeliness and ethical reasons establishing in vivo
dose–response relationships, whilst acceptable for
small numbers of well-characterized compounds, is
often undesirable for comparison of larger numbers
of compounds that maybe synthesized during the
lead optimization phase of drug discovery pro-
grammes. Furthermore, extrapolation of the eﬀective
dose in a pre-clinical disease model to a clinically
relevant dose required for humansmay not be reliable
if based on allometry alone.
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In this review, we describe a data-driven strategy
(Fig. 1) developed during lead optimization studies
that led to the discovery and development of SCYX-
7158 as a potential oral treatment for Human African
Trypanosomiasis (HAT). The strategy employed
target tissue disposition, complemented with in
vitro susceptibility, time-kill and reversibility data
to identify the pharmacokinetic–pharmacodynamic
measures that were associated with eﬃcacy in a
murine model of stage 2 (CNS) HAT. Data are
presented for milestone compounds evaluated during
lead optimization (Fig. 2).
Human African Trypanosomiasis is caused by
infection with the eukaryotic protozoan parasite
Trypanosoma brucei, which is transmitted with the
saliva through the bite of an infected tsetse ﬂy. HAT
currently aﬀects thousands of individuals in sub-
Saharan Africa (WHO, 2006). Complete clearance of
the parasite from the body presents a key tissue
distribution challenge for drug discovery eﬀorts
insomuch as it initially lives in the bloodstream
(Stage 1 disease) of the infected individual, then later
migrates across the blood–brain barrier (BBB) to
establish the fatal, if untreated, central nervous
system (CNS) infection (Stage 2). For complete
cures it is important to maintain therapeutic
drug levels in the haemolymphatic and CNS com-
partments to address both stages of the disease. The
time between initial infection and CNS inﬁltration is
highly variable, and dependent upon the strain of
parasite (e.g. Trypanosoma brucei gambiense vs
Trypanosoma brucei rhodesiense) (Masocha et al.
2007). Because the symptoms of HAT prior to
CNS inﬁltration by the parasite are relatively mild
and non-speciﬁc (e.g. transient fever, general
Fig. 1. Progression pathway during lead optimization of benzoxaboroles as potential treatment for HAT.
Fig. 2. Structures of milestone benzoxaboroles.
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malaise), and good diagnostic tests for the infection
are not available, victims commonly progress to the
CNS stage of the disease prior to seeking treatment.
Drugs to treat HAT, while available, are undesir-
able due to toxicity, diﬃculty of administration and
ineﬀectiveness, particularly with respect to Stage 2
disease. The shortcomings of these treatments are
discussed herein with emphasis on CNS disposition
challenges and how they were addressed during the
discovery of SCYX-7158. Data are compared for
milestone compounds in the optimization campaign:
AN2920, an early anti-trypansomal compound in the
benzoxaborole series; AN3520, the ﬁrst compound
with oral pharmacokinetics commensurate with
eﬃcacy in the acute (Stage 1) murine HAT model,
and SCYX-6759, the ﬁrst compound to achieve 100%
cures in the CNS (Stage 2) murine model following
oral administration.
The optimization strategy employed in vitro
time-kill and reversibility studies complemented
with in vivo exposure data based on the total and
unbound concentrations in plasma and target tissues
to predict whether discovery-phase compounds had
suﬃcient merit to progress to in vivo eﬃcacy models,
and if so, to design dosing regimens based on either
single or multiple daily administrations that were
most likely to provide sterile cures in rodent models.
Taken together, we believe that the strategy,
methods and data presented in this review provide
a valuable starting point for other parasitic disease
targets.
MATERIALS AND METHODS
Materials
Investigational compounds and the deuterium-
labelled internal standard SCYX-5232 were syn-
thesized by SCYNEXIS, Inc. (Research Triangle
Park, NC) and were characterized by 1H-nmr and
LC-MS before use. All compounds were puriﬁed to
>95%. HPLC grade solvents were acquired from
Fisher Scientiﬁc (Pittsburgh, PA). Formic acid
(Fluka Analytical, 598% purity) was purchased
from Sigma-Aldrich (St. Louis, MO) and
ammonium formate (Alfa Aesar, 99% purity) was
purchased from VWR International, LLC (West
Chester, PA). Phosphate buﬀered saline (PBS) was
fromGibco (Invitrogen Corporation, Carlsbad, CA).
Pharmacokinetic studies in mice
The CNS disposition and pharmacokinetics of the
benzoxaboroles were evaluated in infected and
uninfected mice following oral administration.
In vivo phases of single-dose rodent PK studies
were performed at Vivisource (Waltham, MA)
following Institutional Animal Care and Use
Committee (IACUC) review in an Association for
Assessment and Accreditation of Laboratory Animal
Care International (AAALAC)-approved facility.
Studies in Trypanosoma brucei brucei (TREU 667
strain) infected mice, or uninfected satellite animals,
were performed after IACUC review at Pace
University (NewYork, NY).
Male CD-1 or female Swiss Webster mice
(approximately 25 g) were administered test com-
pounds by oral gavage either once (QD) or twice per
day (Q12 h) with doses ranging between 6 and
100mg kg−1 as described below. All compounds
were formulated as an in situ sodium salt in 2% (v/v)
ethanol, 5% (m/v) dextrose, to yield typically clear
colourless solutions that were administered at
4 mL kg−1. Blood samples for pharmacokinetic
studies were collected into polypropylene tubes
containing K2EDTA anticoagulant and stored on
wet ice until centrifuged and processed to plasma.
Plasma was stored at −80 °C. Blood samples from
mice were collected via cardiac puncture under
terminal anaesthesia. Rodents were euthanized in a
CO2 chamber before collection of terminal blood or
tissue samples. Brain tissues were blotted dry and
stored at approximately −80 °C.
Analysis of test compounds in biological samples
Tissue homogenization. On the day of analysis either
fresh tissue (for binding studies) or freshly thawed
tissue samples from PK studies were blotted dry,
weighed and homogenized in 1 volume of PBS. The
density of brain tissue used for the determination of
volume was 1·043 gmL−1 (Allen et al. 1959).
Whole tissue samples were homogenized in parallel
by means of a Precellys® 24 bead mill homogenizer
(Bertin Technologies, France) using 1·5 mL
Precellys tubes containing 1·4 mm diameter ceramic
beads, (CK14), and a single 23 sec cycle of 6500
pulses per minute. Parallel bead homogenization
increased throughput and avoided potential cross-
contamination of samples as each was wholly
contained and homogenized within its own sealed
vial with no direct contact between the homogenizer
instrument or other samples.
After homogenization, an additional volume of
PBS was added to reduce viscosity. All tissue homo-
genates were treated in a bath sonicator at 22 °C for
approximately 5min to remove air bubbles.
Preparation of biological samples for LC-MSMS.
Plasma (50 μL)was treated with 4 volumes of ice-cold
methanol (containing 25 ngmL−1 of either deuter-
ium (d6)-labelled SCYX-7158 internal standard
(SCYX-5232) for SCYX-7158 analyses or a related
benzoxaborole for other compounds) to precipitate
proteins. Treated samples were gently mixed on a
96-well plate shaker for approximately 10min then
centrifuged at approximately 3000 g and 15 °C for
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15min. Supernatants were transferred to fresh
96-well plates for analysis by means of LC-MSMS.
Samples of tissue homogenate (50 μL), or buﬀer from
protein binding studies, were treated similarly to
plasma samples.
Calibration standards and quality control samples
were prepared in matched drug-free matrix prepared
by combining homogenized tissues from control
animals. Drug-free tissues and plasma were obtained
from Bioreclamation, Inc. (Westbury, NY).
High-performance liquid chromatography with tandem
mass spectrometry (LC-MSMS). All biological
samples were assayed by a veriﬁed LC-MSMS
method employing two dimensional chromato-
graphic separation to overcome ion suppression
(Annesely, 2003) caused by co-elution of endogenous
components with benzoxaboroles. In summary,
treated samples were loaded onto Phenomenex
(Torrance, CA) Synergi Polar RP, 4 μ, 50×2mm
extraction columns and subsequently back-eluted
onto a Phenomenex Luna C8(2) 3 μ, 50×2mm
analytical columns protected by a Phenomenex C8
guard cartridge. Mobile phases for extraction and
analytical columns consisted of 5mM ammonium
formate and 0·1% (v/v) formic acid in water (A), and
5mM ammonium formate and 0·1% (v/v) formic acid
in methanol (B). Samples were loaded onto the
extraction column in 40% B and back-eluted onto the
analytical column using a linear gradient to 50% B
between 0·55 to 1·55min after loading the sample. A
linear gradient from 5 to 95% B over 4.5 min was
employed for analytical chromatography. Test com-
pounds eluted at approximately 3min, and the total
run time was 6min.
The instrumentation for two dimensional LC-
MSMS comprised two Agilent 1100 series pumps
(Agilent Technologies Inc., Santa Clara, CA), inter-
faced to either a API-3000 or API-4000 triple
quadrupole mass spectrometer (Applied Biosys-
tems, Foster City, CA) via a turbo-ion electrospray
source operated in positive ionization mode. Eluent
ﬂow between extraction and analytical columns
and the mass spectrometers was directed using two
Valco 10-port valves (Valco Instruments Company
Inc., Houston, TX). Samples were introduced
to the system via CTC Pal Autosampler (Leap
Technologies, Carrboro, NC) set to inject 20 μL
aliquots of sample extract through a 10 μL sample
loop. The liquid chromatography system and all
peripherals were controlled from within Analyst
V.1.4.2 software.
Instrumental conditions for the mass spectrometer
and precursor to product ion transitions were selected
and optimized for sensitivity and selectivity. The
MS/MS transitions for AN2920, AN3520, SCYX-
6759 and SCYX-7158 were 292·2/133·2, 322·0/89·2,
340·1/191·1 and 368·0/191·0, respectively.
In vitro prediction of BBB permeability and
Pgp-mediated eﬄux transport
The propensity of test compounds to cross the BBB
was examined using an in vitro MDCKII-hMDR1
monolayer assay (Polli et al. 2001). In summary,
MDCKII-hMDR1 cells (Netherlands Cancer
Institute, Amsterdam, the Netherlands) were seeded
at a density of 3×105 cells per well onto microporous
polycarbonate membranes in 12 well Costar
Transwell plates (Corning Inc., Lowell, MA). The
cells were incubated for 3 days during which time
they formed conﬂuent monolayers. Trans-epithelial
resistance (TEER) was measured for each insert to
ensure the integrity of the monolayer (acceptable
TEER >160Ω cm2). The permeability and suscepti-
bility for Pgp-mediated eﬄux was evaluated by
adding each compound at a concentration of 3 μM,
in the presence or absence of 2 μM GF120918
(a potent Pgp inhibitor), to the apical compartment.
Competency of the Pgp eﬄux transporter was
conﬁrmed by assay of propranolol (non-substrate)
and amprenavir (substrate). Cell monolayers were
incubated in triplicate with shaking (160 rpm) at
37 °C in a 5% CO2-enriched humidiﬁed atmosphere
for 1 h. Samples were removed from the apical
and basolateral compartments after incubation and
assayed for test compound concentrations by LC-
MSMS. Values for mass balance, PappA−B,
PappA−B+GF918, and absorption quotient (AQ)
were calculated for each compound (Troutman
and Thakker, 2003; Thiel-Demby et al. 2004).
Acceptance criterion for mass balance was 70–120%.
Plasma protein and tissue binding
Binding to plasma proteins, brain homogenates or
proteins in serum-fortiﬁed HMI-9 media was deter-
mined by rapid equilibrium dialysis (RED) (Pierce,
Rockford, IL) using a 48-well plate-based format
according to the manufacturer’s instructions. Brieﬂy,
test compound was added to fresh plasma
(Bioreclamation, Liverpool, NY) at the required
concentrations, freshly prepared brain homogenate
or media. Duplicate aliquots of each sample were
transferred into the sample chambers of the RED
devices, and dialysis buﬀer (BupHPBS)was added to
the buﬀer chambers. The plates were sealed and
incubated at 37 °C for 4 h. After dialysis, samples
collected from the buﬀer and tissue chambers were
treated with ice-cold methanol (3 volumes for plasma
or HMI-9 media, 4 volumes for brain) to precipitate
proteins. The treated samples were centrifuged for
10min at approximately 3000 g at 15 °C. The
supernatants were assayed for test compound by
LC-MSMS. Calibration standards and quality con-
trol samples were prepared in matched matrix and
assayedwith samples. Values for unbound and bound
fractions and mass balance were calculated.
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Concordance of binding for each batch of plasma was
conﬁrmed by assay of warfarin, imipramine and
carbamezapine. Acceptance criterion for mass bal-
ance was 70–120%.
In vitro time-kill assays and reversibility of
trypanocidal eﬀects
The time and concentration dependency for
oxaborole-mediated killing of T. b. brucei, under
constant (time-kill) and transient (reversibility)
drug-pressure, was determined as described pre-
viously (Nare et al. 2010).
In summary, time-kill kinetics were determined
using the CellTiter Glo kit (Promega Inc., Madison,
WI) to measure trypanosome ATP content as a
real-time indicator of viability. Test compounds
were evaluated over the concentration range 0·01–
10·0 μgmL−1 to provide concentrations from sub-
therapeutic levels to >5 fold the predicted minimum
inhibitory concentrations (MIC) or maximal eﬀects.
Test solutions were prepared in HMI-9 media and
dispensed into white wall-clear bottom 96-well plates
(Corning Inc., Lowell,MA). Trypanosomes (1×104)
were added to each well, incubated at 37 °C/5% CO2
and, at speciﬁed time intervals, CellTiter Glo reagent
was added to lyse parasites. Plates were incubated
for a further 10min in the dark whereupon lumines-
cence was determined using an EnVision Multilabel
plate reader (Perkin Elmer, Waltham, MA). Time-
kill parameters were determined from plots of parasite
viability vs incubation time for each concentration
tested. All incubations were performed in triplicate
and data are presented as composite mean values.
Reversibility was assessed as the ability T. b. brucei
parasites to recover from transient exposure
(0–24 h) to test benzoxaboroles (0·02–10 μgmL−1).
Trypanosomes were seeded in clear 96-well
‘V’-bottom plates at a density of 1×105 parasites
per well; one plate was prepared for each time-point.
After the designated incubation time, each plate was
removed from the incubator and centrifuged at
4400 g for 5 min to sediment parasites. The super-
natant containing the test compound was aspirated
and three washing cycles were performed where
100 μl of warmed HMI-9 media was added to each
well and then aspirated. After washing, the parasites
were re-suspended in 100 μl of warmed media and
3×20 μl aliquots of each suspension were transferred
to fresh plates containing 80 μl of fresh HMI-9 media
per well. Thus, each concentration and time-point
was evaluated in triplicate. Each plate was incubated
for a further 72 h, whereupon, trypanocidal activity
was determined using resazurin (Sigma-Aldrich,
St. Louis, MO) where 20 μl of a 25mg/100mL
stock in PBS was added, incubated for an additional
4–6 h and ﬂuorescence measured using the EnVision
plate reader (excitation wavelength, 530 nm and
emission wavelength, 590 nm).
The eﬀects of serum proteins on trypanocidal activity
To assess the potential eﬀects of protein binding on
trypanocidal activity, parasite viability assays were
performed in the presence of increasing concen-
trations (2·5–50%) of foetal calf serum (Invitrogen,
Carlsbad, CA) in HMI-9 media.T. b. brucei parasites
were conditioned to the test serum concentrations for
at least one round of passage prior to assay. Test
compounds were added, incubated for 72 h, signal
measured and IC50 determinations were conducted
as described above using the resazurin endpoint. The
fold change in IC50 from minimal serum concen-
tration to maximal serum concentration was calcu-
lated and used to compare compounds and their
potential for being restrictively protein bound.
Eﬃcacy in the murine model for chronic
(Stage2, CNS) HAT
The eﬃcacy of benzoxaboroles was evaluated in a
murine model of Stage 2 (CNS) HAT (Nare et al.
2010; Jacobs et al. 2011). In summary, mice (n = 10
per group) were infected by bolus i.p. injection of
1×104 T. b. brucei (TREU 667) parasites. A single
bolus i.p. dose (10mg kg−1) of berenil (Sigma-
Aldrich, St. Louis, MO) was administered on day 4
as a positive treatment control for haemolymphatic-
stage infection. Infection of the remaining animals
proceeded for 21 days to establish a CNS infection
before treatment with either a single dose of berenil
(as above) or test compounds by the oral route either
once or twice daily over 7 days at the doses indicated
below. Animals were checked at least weekly for
parasitaemia and were immediately removed from
cages and euthanized upon recrudescence. Animals
were considered cured if they were aparasitaemic for
at least 180 days after treatment.
RESULTS AND DISCUSSION
Until recently, progress towards new treatments for
HAT had been slow, owing to a lack of commercial
interest and, most notably, a poor understand-
ing of CNS disposition and pharmacokinetic–
pharmacodynamic (PK–PD) relationships for
Stage 2 drugs in particular. This shortcoming is
currently being addressed by academic and non-
proﬁt drug research and development (R&D)
organizations including the Drugs for Neglected
Diseases initiative (DNDi), whose success has been
demonstrated by delivery of two HAT compounds,
Fexinidazole (Torreele et al. 2010) and SCYX-7158
(Jacobs et al. 2011), into clinical development. The
target product proﬁle (TPP) for these new agents
included the requirement for oral delivery and the
ability to treat both stages of the disease using a single
dosing regimen. The PK–PD strategy described
herein reﬂects the approach developed for the
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optimization and selection of SCYX-7158 as a pre-
clinical and clinical candidate for the treatment of
Stage 1 and Stage 2 HAT.
Pharmacokinetic–pharmacodynamic measures
Pharmacokinetic–pharmacodynamic (PK–PD) re-
lationships establish whether a drug’s eﬃcacy in-
creases with dose and, if so, help determine which PK
parameter can best be used with MIC to predict
outcome. Typical measures used to predict eﬃcacy
are summarized in Fig. 3 and include: (a) the time
above MIC (t>MIC), (b) the ratio of peak concen-
tration andMIC (Cmax/MIC), (c) the ratio of the area
under the concentration vs time proﬁle (AUC) while
concentration is greater than MIC, or (d) the ratio of
the area under the concentration vs time proﬁle
(AUC) measured over the dosing interval or 24 h
to MIC (AUC0− t/MIC) (Mueller et al. 2004). The
most predictive measure guides whether an opti-
mized dosing regimen employs either a fewer number
of larger doses where eﬃcacy is driven by Cmax,
or more frequent but lower doses to maintain an
AUC/MIC (average concentration/MIC) multiple.
In either regimen it is generally desirable to maintain
tissue concentrations above the MIC throughout the
treatment period to lower the risk of the target
organism generating resistance.
Target tissue disposition for HAT
CNS disposition challenges for currently approved
Stage 2 HAT drugs. One current ﬁrst line treatment
for Stage 2 HAT, melarsoprol, has been shown to be
highly toxic, causing drug-induced death in 2–10%
of patients (Schmid et al. 2004; Doua et al. 2005;
Kuepfer et al. 2012). Nonetheless, it is active in
treating both T. b. gambiense and T. b. rhodesiense.
Reports of treatment failures with melarsoprol
(Matovu et al. 2001) are suggestive of development
of drug resistance (Delespaux and de Koning, 2007)
although evidence of signiﬁcant change in the
sensitivity of T. b. gambiense strains to melarsoprol
appears elusive (Likefack et al. 2006). Another
possibility is that treatment failures may arise from
inconsistent or inadequate CNS exposure of this
drug. Indeed, failure to achieve sustained cerebrosp-
inal ﬂuid (CSF) exposure (a surrogate for the
unbound fraction in brain tissue (Shen et al. 2004;
Summerﬁeld and Jeﬀrey, 2006; Lin, 2008)) is
thought to contribute to the high (3–30%) failure
rate with melarsoprol treatment (Legros et al.
1999). Pre-clinical and clinical studies support this
claim. Following intravenous administration (doses
of 2·2–3·6 mg kg−1) maximum concentrations of
melarsoprol in the CSF of uninfected vervet monkeys
were very low (*50 ngmL−1) despite serum
levels of the drug being substantially higher
(1·7–3·8 μgmL−1) (Burri et al. 1994). Equivalent
concentrations of melarsoprol have been reported
in both the serum (0·87–2·2 μgmL−1) and CSF
(39–79 ngmL−1) of human patients 24 h after the
last injection of a multi-day treatment regimen (Burri
and Keiser, 2001). The in vitro MIC reported for
melarsoprol is 2–100 ngmL−1 (Burri et al. 1994)
suggesting therapeutic levels may neither be achieved
nor sustained. Increasing dose is contra-indicated
because of a higher risk of melarsoprol-induced
encephalopathy.
Fig. 3. Representation of the potential pharmacokinetic–pharmacodynamic measures for modeling.
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An alternative treatment for Stage 2 HAT,
eﬂornithine, while better tolerated than melarsoprol,
is potentially less attractive because it is active only
against T. b. gambiense and must be administered by
large intravenous infusion doses (400 mg kg−1 day−1)
four times per day over fourteen days (Priotto et al.
2008). This treatment paradigm is very diﬃcult to
achieve in disease-endemic regions. Recently, clinical
studies have shown that treatment duration maybe
shortened to 7 days using a combination therapy
of nifurtimox and twice daily eﬂornithine (Priotto
et al. 2007); however, the complexity of parenteral
administration remains.
Like melarsoprol, CNS exposure of eﬂornithine
is limited. In mice, maximum concentrations of
eﬂornithine only reach 10–40 nM, representing <0·1%
of the administered eﬂornithine dose, and far below
the reported in vitro MIC for the drug (ca. 50 μM)
(Sanderson et al. 2008). In this study, the authors
included uninfected mice as controls to allow
comparison of CNS exposure in healthy animals to
those infected withT. b. bruceiGVR35, a strain of the
parasite commonly used in murine models of Stage 2
HAT (Jennings and Gray, 1983) as it readily
establishes a CNS infection. The permeability of
eﬂornithine across the BBB was similar between
infected and uninfected animals for 21 days following
infection, although greater permeability was ob-
served for late-stage infected mice at days 28 and 35
post-infection. Sanderson et al. (2009) have also
reported that the integrity of the BBB is maintained
until late stage CNS infection. These observations,
coupled with reports of interactions of T. brucei with
the BBB in both in vitro (Grab et al. 2004) and in vivo
(Masocha et al. 2007) models suggest a dynamic
translocation of parasites between the periphery and
the brain, with only modest modiﬁcation of the BBB.
Consequently, stage 2 drugs must be able to
circumvent the physical and biological barriers
present in the fully intact BBB to the extent that
they achieve and maintain therapeutic levels within
brain parenchyma and CSF. Reports for the phar-
macokinetics of eﬂornithine in human patients
are sparse but are consistent with those derived
from animal models, suggesting that CSF levels
of eﬂornithine at steady state are generally low
(5–150 nM) relative to concentrations required to be
eﬃcacious in vitro (Milford et al. 1993).
Progression pathway and identiﬁcation of
pharmacokinetic–pharmacodynamic measures
based on unbound target tissue exposure
A data-driven strategy (Fig. 1) was developed during
lead optimization studies for SCYX-7158 that has
broad applicability in drug discovery for parasitic
disease targets. The strategy employs ‘Tier 1’ in vitro
metabolism and disposition assays, with in vitro
parasite susceptibility assays, to prevent progression
of compounds that would likely fail in animal
infection models. Tier 1 assays may also prioritize
compounds for ‘Tier 2’ in vivo target tissue
disposition, and in vitro time-kill and reversibility
assays used to identify the pharmacokinetic–
pharmacodynamic measures that may be associated
with eﬃcacy in animal infection models such as the
murine model of Stage 2 (CNS) HAT. In vitro and in
vivo PK–PD measures may then be correlated to
provide a rationale for clinical dosing regimens.
Tier 1: goals for potency and drug-like properties during
lead optimization
In vitro susceptibility of T. brucei. Demonstration
of in vitro potency and selectivity against a target
organism vs host is typically the ﬁrst hurdle in
advancing a compound through the progression
pathway to pre-clinical candidate selection. The
milestone oxaborole carboxamides (Fig. 2, Table 1)
each exhibited potent activity against T. b. brucei,
T. b. rhodesiense and T. b. gambiense in vitro, and
achieved >40 fold selective inhibition of parasite
compared to the L929 mammalian cell line employed
as an in vitro predictor of cytotoxicity and therefore
selectivity (Nare et al. 2010). The IC50 is deﬁned as
the concentration of compound that is required to
decrease parasite viability by 50%, and the minimum
inhibitory concentration (MIC) is the lowest con-
centration that completely inhibits parasite growth
(Jacobs et al. 2011).
In vitro DMPK assays: establishing drug-like
properties. Compounds with in vitro anti-parasitic
activity must also demonstrate adequate ‘drug-like’
properties; namely, solubility, in vitro metabolic
stability in the presence of liver sub-cellular
fractions (typically microsomes or S9 fraction)
(Mandagere et al. 2002), non-restrictive binding to
plasma proteins (Mackichan, 2005; Summerﬁeld
et al. 2006) and, for oral compounds, permeability
in either MDCKII-hMDR1 or Caco-2 monolayer
assays (Mandagere et al. 2002). The latter can also
provide insight on the compound’s ability to cross
blood-tissue barriers such as the blood–brain, blood-
testicular or blood-retinal barriers, and interact with
drug eﬄux or uptake transporters that can either
attenuate or enhance disposition within a target
tissue.
The ability of a drug to cross the BBB and gain
entry into the CNS compartment reﬂects interplay
between membrane permeability, protein binding
and drug transporters, notably eﬄux transporters
such as P-glycoprotein (Pgp) or Breast Cancer
Related Protein (BCRP). It is also worth considering
that these parameters may impact the ability of a
compound to penetrate the target parasite.
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In a study comparing the properties of CNS and
non-CNS antihistamines, compounds with high
brain-to-plasma concentration ratios typically
achieved high passive permeability (>150 nm s−1)
in MDCK-MDR1 transport assays, moderate
protein binding (<84%), and were not Pgp substrates
(Mahar Doan et al. 2004). In contrast, compounds
with low brain-to-plasma ratios typically displayed
low passive permeability (<100 nm s−1), were sub-
strates for Pgp and had higher binding to plasma
proteins. Exceptions, such as terfenidine, were noted
which, although being Pgp substrates, had high
passive permeability that was able to overcome the
transporter-mediated eﬄux (Polli et al. 2001). In
vitro permeability, although a helpful predictor of
CNS penetration, reﬂects the potential rate and is a
surrogate for the actual extent of brain drug delivery.
The latter is the more helpful parameter for devel-
oping models and data on unbound tissue exposure
are preferred for developing PK–PD models.
In vitro protein binding and permeability data for
the milestone benzoxaboroles during the discovery of
SCYX-7158 are presented in Table 2. Oxaboroles as
a class generally met the criteria for CNS penetration
with milestone compounds demonstrating very high
permeability values (PappA–B, >350 nm s
−1) in the
MDCK-MDR1 transport assay, and were not sub-
strates for the Pgp eﬄux transporter (AQ<0·3
(Thiel-Demby et al. 2004)). Less desirably, protein
binding was modest to high 93·2–98·7% and likely
hampered CNS penetration such that in single-dose
studies in mice the brain to plasma ratio was typically
less than unity (Fig. 4). Protein binding was also
a concern because it may also attenuate in vivo
potency.
Serum shift assay and the impact of drug binding to
plasma proteins or tissues on potency. Drug distri-
bution in plasma and tissue reﬂects equilibrium
between bound and unbound (free) fractions, where
the unbound fraction is deemed to be pharmacologi-
cally active and also the target for drug clearance
mechanisms. As unbound drug is cleared from a
compartment either by elimination mechanisms
or, for example, uptake into a target cell or parasite,
bound drug in plasma or tissue interstitial spaces
dissociates to re-establish the equilibrium. Restric-
tive or non-restrictive binding has been used quali-
tatively to describe the dissociation rate (Kd) that,
rather than the binding extent, inﬂuences whether
binding impacts potency (Fig. 5) (MacKichan,
2005). Despite its importance, Kd is rarely measured
during lead optimization of ‘small molecule’ drugs
owing to the complexity of the measurement. More
frequently, the in vitro ‘serum-shift’ assay is per-
formed as a surrogate that assesses the impact of
increasing serum concentration on potency (IC50).
In this assay, the trypanocidal activity of benzo-
xaboroles appeared only modestly attenuated byT
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serum. In a comparison, the fold changes in IC50
between 2·5 and 50% calf serum for SCYX-7158 and
suramin were 3·6 and 26, respectively, suggesting
SCYX-7158 is less restrictively bound (Fig. 6).
A marked loss in potency in a serum-shift assay
provides a warning that in vitro potency in a low
serum media may not translate to in vivo eﬃcacy
where the candidate drug maybe bound thereby
achieving sub-therapeutic concentrations. As a gen-
eral strategy it is more reliable to build PK–PD
models based on unbound concentration in the target
compartment rather than total drug levels.
Table 2. Comparison of in vitro protein binding and MDCKII-hMDR1 permeability
In vitro study
Compound
AN2920 AN3520 SCYX-6759 SCYX-7158
Binding to plasma
protein
Human plasma
(1 μgmL−1, n=3)
Fraction bound (%) 93·2±0·836 95·3±0·425 97·7±0·053 98·7±0·018
Unbound fraction (%) 6·8 4·7 2·3 1·3
Mass balance (%) 106 110 97 110
MDCK-MDR1
Permeability
Incubation concentration (μM) 3 3 3 3
Papp, A–B direction (nm s−1) 438 424 379 414·8
Papp, A–B direction+GF918
(nm s−1)
465 434 386 426·9
Mass balance
(A–B, A–B+GF918, %)
94%, 99% 92%, 90% 89%, 95% 79%, 75%
Absorption quotient 0·06 0·02 0·02 0·03
P-gp classiﬁcation Non-substrate Non-substrate Non-substrate Non-substrate
Fig. 4. Total concentration vs time curves for AN2920, AN3520, SCYX-6759 and SCYX-7158 in male CD-1 mice
following a single oral dose. Data are normalized to a 50mg kg−1 dose to allow direct comparison of exposure between
compounds. The MIC line is deﬁned as the lowest concentration of each compound that completely inhibits visible
parasite growth. Data points for plasma (solid lines) and brain (dotted lines) represent a single mouse at each time point.
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Unbound fraction and concentrations in target tissues.
CSF has been employed successfully as a surrogate
for the unbound fraction in brain tissue. However,
systemic drugs can enter the CSF by 2 main routes;
either indirectly via passage across the BBB followed
by diﬀusion from the brain interstitial ﬂuid into the
CSF, or directly via passage across the choroid
plexus. In the latter instance, drug in CSF would
thus not represent unbound concentration in brain
interstitial ﬂuid. A further complication of using
CSF is the practical challenge of collecting an
adequate volume from mice that is also free of
contamination by blood. Consequently, in vitro
ultraﬁltration or equilibrium dialysis techniques,
with either fortiﬁed samples of tissue homogenate
or ex vivo tissue samples (Fridén et al. 2007; Watson
et al. 2009), are most practicable for assessing
unbound concentrations in tissues.
At steady state, permeable compounds unaﬀected
by active uptake or eﬄux mechanisms should achieve
generally similar unbound concentrations in tissue
and plasma although the unbound fractions may
diﬀer. The binding of SCYX-7158 to mouse and
human plasma was concentration dependent, with
the unbound fraction increasing from 0·3 to 4·6% and
from 0·3 to 3·9% in mouse and human plasma,
respectively (Fig. 7). The most rapid increase in the
unbound fraction occurred between 0·1 and
10 μgmL−1 SCYX-7158. Interestingly, the binding
to mouse brain tissue was generally similar across the
concentration-range studied (Fig. 7). The relation-
ship between unbound fraction in each matrix and
total concentration was calculated to allow conversion
from total to free concentrations in PK studies. The
SCYX-7158 concentration dependent binding to
proteins in the cell culture media used for in vitro
trypanosomal assays was also determined to allow
analysis of time-kill and reversibility data, based on
free concentrations and to identify the IC50u and
MICu based on free concentration.
To progress to Tier 2 assays, a compound should
be non-cytotoxic to mammalian cells and suitable for
administration by a route and dose likely to achieve
and ideally maintain5ED90 unbound concentration
in plasma or tissue.
Tier 2: goals for tissue disposition and eﬃcacy
in infection models
In vitro time-kill and reversibility of exposure to
benzoxaboroles. Time kill and reversibility curves
based on total drug exposure for the milestone
benzoxaboroles, including SCYX-7158, have been
reported previously (Nare et al. 2010; Jacobs et al.
2011). In summary, time-kill studies demonstrated
that the onset of trypanocidal behaviour was rapid
(<24 h) and concentration dependent, reaching
maximal eﬀect at approximately 4 fold the MIC.
Fig. 5. Representation of restrictive and non-restrictive binding.
Fig. 6. Impact of serum on the in vitro potency of
SCYX-7158 and suramin as determined by means of the
serum-shift assay. Data represent fold change in IC50
against T. b. brucei relative to the lowest serum
concentration evaluated (2·5%). IC50 values were
determined from composite mean values for triplicate
assays at each concentration of either SCYX-7158 or
suramin.
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Transient exposure to benzoxaboroles in reversibility
studies further demonstrated that a persistent eﬀect
on trypanosome survival was dependent on both
exposure time and concentration.
To elucidate whether either drug concentration,
AUC/MIC or exposure time have the greater im-
pact on trypanosome survival, and to allow corre-
lation between in vitro and in vivo eﬃcacy
endpoints, exposure time and concentration in the
reversibility assay were considered in the context of
exposure expressed as AUC (area under the concen-
tration vs time curve) for unbound concentrations
(Fig. 8).
The lowest AUC aﬀording a 100% trypanocidal
eﬀect (5·81 μg hmL−1) was achieved following
incubation with an unbound concentration of
0·242 μgmL−1 (Ct, 0·625 μgmL
−1) SCYX-7158
for 24 h. Interestingly, at the next highest concen-
tration studied (Cu, 1·11 μgmL
−1 equivalent to a Ct,
1·25 μgmL) this target AUC was achieved by 6 h;
Fig. 7. The concentration dependent in vitro binding of SCYX-7158 to mouse and human plasma, and mouse brain
tissue determined by equilibrium dialysis. Binding studies were performed in fresh tissues, each data point represents
the mean of at least triplicate measurements.
Fig. 8. In vitro reversibility plots with presenting survival of T. b. brucei vs cumulative AUC based on unbound
concentration. Experiments were conducted in triplicate and represent survival of treated parasites expressed as a
percentage relative to untreated parasites.
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however, parasites were able to tolerate the higher
concentration, for 8 h without impact on survival
thereby suggesting treatment time rather than absol-
ute concentration maybe the more important factor
in determining eﬃcacy. This observation will be
important when designing a dosing regimen for in
vivo eﬃcacy studies because it implies sustaining
exposure above an MIC level (AUC/MIC) maybe
more important than achieving a maximum concen-
tration. Further, tolerability in clinical treatment
regimens is often limited by the maximum concen-
tration achieved shortly after dosing so the opportu-
nity for lower doses and hence more modest maximal
concentrations may improve safety margins and
patient compliance.
In vivo pharmacokinetics and CNS penetration of
oxaboroles. Total brain concentration is a helpful
ﬁrst step in assessing CNS penetration relative to
MIC to prevent progression of compounds that do
not achieve suﬃcient exposure and would likely fail
in Stage 2 eﬃcacymodels. A standard in vivo protocol
would involve dosing the target pre-clinical eﬃcacy
species, usually rodents, by intended administration
route and then collecting paired blood and tissue
samples at selected times post-dose to allow calcu-
lation of the tissue-to-plasma (or whole blood) ratio
for each sample pair and, more reliably, the ratio
based on overall exposure (AUC, area under the con-
centration vs time proﬁle). Total brain exposure is
ﬁrst corrected for the amount of drug in the residual
blood using the following parameters: plasma
volume, *15 μl g−1 brain tissue (Vérant et al. 2007;
Fridén et al. 2009), murine microvascular haemato-
crit, 30% (Vérant et al. 2007); density of brain tissue,
1·043 gmL−1 (Allen et al. 1959), and density of
blood 1·046 gmL−1 at 30% haematocrit (Friedman,
1959).
AN2920, the original lead compound, achieved
moderate plasma exposure maintaining concen-
trations above its MIC to approximately 7 h post
dose, consistent with Stage 1 eﬃcacy (Fig. 4); but
CNS exposure above MIC was only achieved for 1 h.
AN3520 was selected based on improved plasma
exposure and potency and modestly extended CNS
exposure; but concentrations in CNS were not
consistent with likely eﬃcacy in the CNS model of
the disease even if dosed twice daily. In contrast,
SCYX-6759 and SCYX-7158 maintained total CNS
concentrations above theirMIC for approximately 10
and 20 h, respectively, potentially consistent with
twice or once daily dosing in a Stage 2 model. Both
compounds were progressed to dose range-ﬁnding
studies in acute and chronic murine models of HAT
(Nare et al. 2010; Jacobs et al. 2011). PK–PDmodels
based on the unbound brain concentrations of
SCYX-7158 vs cure rate in the chronic HAT model
are described below.
Tier 3: Pharmacokinetics–pharmacodynamics
Pharmacokinetics–pharmacodynamics of SCYX-7158
in the Stage 2 (CNS) murine HAT model. In vitro
reversibility assays for SCYX-7158 indicated that
exposure time and AUC/MIC were important in
predicting eﬃcacy. The minimum AUC based
on unbound concentration and 24 h exposure for
complete and irreversible inhibition of parasite
growth was 5·81 μg hmL−1. This corresponds to a
target average unbound concentration at steady-
state (CuSS(AVE)) in brain of 0·242 μgmL
−1 which,
by deﬁnition, corresponds to the unbound MIC.
Tantalizingly, partial trypanocidal activity, 24%
reduction in survival relative to untreated control
parasites (Fig. 8), was also observed in the re-
versibility assay at a lower concentration (Cu,
0·123 μgmL−1; Ct, 0·313 μg.mL
−1) after 24 h incu-
bation, thereby suggesting that prolonging exposure
may allow for a lower dose.
Pharmacokinetic studies were performed in CD-1
mice to establish AUC0–24 following single and
7×once daily oral doses of 6·25, 12·5, 25, 50 and
100mg kg−1 SCYX-7158 (Jacobs et al. 2011).
Steady-state data were generated in uninfected mice
dosed concurrently with those being treated follow-
ing infection with T. b. brucei (TREU 667) for the
Stage 2 HAT model. Values for unbound AUC0–24
in brain were calculated using the single and
steady-state exposure data (non-parametric super-
positioning indicated steady-state was mostly at-
tained on day 2 so day 7 data were employed for
days 2–7 rather than modelled data for days 2–6) and
compared to the target unbound AUC from the in
vitro reversibility studies (Fig. 9).
All animals treated with the lowest oral dose
(6·25 mg kg−1 day−1) for 7 days were cleared of
haemolymphatic T. b. brucei but demonstrated
recrudescence of parasitaemia around day 35 after
infection. Treatment with 12·5 mg kg−1 SCYX-7158
once daily for 7 days achieved an 80% cure rate, and
higher doses (525mg kg−1 day−1) aﬀorded com-
plete cures. Comparison of unbound AUC0–24 in
brain tissue (Fig. 9) on study days 1–7 demonstrated
that animals receiving 25mg kg−1 approached the
reversibility assay MICu AUC0–24 (5·81 μg hmL
−1)
on day 1 (4·98 μg.hmL−1) and exceeded it for
treatment days 2–7 (7·15 μg.h mL−1) suggesting
that the reversibility data were predictive of eﬃcacy.
Interestingly, the unbound AUC0–24 for the animals
receiving 12·5 mg kg−1 SCYX-7158 was approxi-
mately 50% of the target MICu AUC (day 1,
2·41 μg.hmL−1 and day 2–7, 2·98 μg.h mL−1) yet
yielded 80% cures, thus suggesting prolonged
exposure at lower AUC can achieve cures.
Examination of the unbound concentration vs
time curves (not shown) for the animals receiving
12·5 mg kg−1 SCYX-7158 indicated that unbound
plasma concentrations in brain tissue exceeded the
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MICu (0·242 μgmL
−1) and IC50u (0·082 μgmL
−1)
for only 4 and 10 h, respectively on each day. In vitro
reversibility data indicated that both exposure time
and AUC are important for eﬃcacy and thus the
administration of the 12·5 mg kg−1 as a divided dose
(2×6·25mg kg−1) on a Q12 h regimen may improve
eﬃcacy beyond 80% by maintaining exposure for
longer, albeit with lower values for Cmax. This
hypothesis could be also evaluated in vitro by
extending exposure times in the reversibility assay.
The need for continued exposure was further
indicated in a separate murine Stage 2 HAT study
where infected mice were treated with 50mg kg−1
SCYX-7158 for either 1, 3, 5 or 7 days. As expected, a
single oral 50mg kg−1 dose achieved an unbound
AUC0–24 (18·2 μg hmL
−1) that markedly exceeded
the in vitro MICu AUC (5·8 μg hmL
−1) allowing
animals to achieve a potentially therapeutic CNS
exposure after a single treatment; however, 100%
cure rates were only achieved after 53 days of
dosing. No animals were cured after a single dose,
thereby suggesting in vivo exposure beyond 24 h is
required.
CONCLUSIONS
In conclusion, we have successfully utilized a data-
driven strategy based on target tissue disposition,
complemented with in vitro susceptibility, time-kill
and reversibility assays to deliver SCYX-7158 as a
potential oral treatment for stage 2 (CNS) HAT. The
in vitro reversibility assay was employed to correlate
exposure based on unbound concentrations with
activity, and to identify that exposure time with
AUC/MIC were the PK–PD measures that would
best predict eﬃcacy in a murine model of chronic
(CNS) HAT. Finally, pharmacokinetic studies in
uninfected mice dosed concurrently with those
infected with T. b. brucei (TREU 667) demonstrated
that 100% cure rates are achieved when the unbound
AUC0–24 in brain tissue meets or exceeds the MICu
AUC determined in the in vitro reversibility assay.
Both the in vitro reversibility assay and the murine
model suggest that cures maybe achieved at a lower
exposure providing exposure is maintained for
extended periods. Additional studies to explore this
possibility further are planned and will be reported in
due course.
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